Filter

Refine by date

—

Refine by collections

  • Print
  • Save

Search Results

You are looking at 1 - 10 of 11 items for :

Clear All
Carla Colombo Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Carla Colombo in
Google Scholar
PubMed Close
,
Daniele Ceruti Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Daniele Ceruti in
Google Scholar
PubMed Close
,
Massimiliano Succi Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Massimiliano Succi in
Google Scholar
PubMed Close
,
Simone De Leo Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy

Search for other papers by Simone De Leo in
Google Scholar
PubMed Close
,
Matteo Trevisan Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy
Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Matteo Trevisan in
Google Scholar
PubMed Close
,
Claudia Moneta Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Claudia Moneta in
Google Scholar
PubMed Close
, and
Laura Fugazzola Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Laura Fugazzola in
Google Scholar
PubMed Close

previous study ( 16 ) are included in the present series. Thirty-one out of 36 patients were MKIs-naive, and 5 out of 36 were on second-line treatment, as patients on SELP were previously treated with VAN. The clinical–pathological features and treatment

Article Type:
Research Article
Collections:
Thyroid cancer - basic and translational
DOI:
https://doi.org/10.1530/ETJ-23-0246
Volume/Issue:
Volume 13: Issue 3
Open access
Andrew G Gianoukakis The Lundquist Institute at Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA, Torrance, California, USA

Search for other papers by Andrew G Gianoukakis in
Google Scholar
PubMed Close
,
Jennifer H Choe Department of Medicine, Duke University Medical Center/Duke Cancer Institute, Durham, North Carolina, USA

Search for other papers by Jennifer H Choe in
Google Scholar
PubMed Close
,
Daniel W Bowles Division of Medical Oncology, University of Colorado, Aurora, Colorado, USA

Search for other papers by Daniel W Bowles in
Google Scholar
PubMed Close
,
Marcia S Brose Department of Otorhinolaryngology: Head and Neck Surgery, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, USA

Search for other papers by Marcia S Brose in
Google Scholar
PubMed Close
,
Lori J Wirth Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA

Search for other papers by Lori J Wirth in
Google Scholar
PubMed Close
,
Taofeek Owonikoko Winship Cancer Institute of Emory University, Atlanta, Georgia, USA

Search for other papers by Taofeek Owonikoko in
Google Scholar
PubMed Close
,
Svetlana Babajanyan Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, USA

Search for other papers by Svetlana Babajanyan in
Google Scholar
PubMed Close
, and
Francis P Worden Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, USA

Search for other papers by Francis P Worden in
Google Scholar
PubMed Close

become refractory to RAI therapy ( 2 ). The prognosis for these patients is poor, and the 10-year survival rate for RAI-refractory (RAI-R) thyroid cancer is 10% ( 3 ). Multi-kinase inhibitors (MKIs) are the standard of care for RAI-R DTC. While MKIs are

Article Type:
Research Article
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-23-0039
Volume/Issue:
Volume 13: Issue 1
Open access
Stacey A. Fedewa Surveillance and Health Services Research, American Cancer Society, Atlanta, Ga., USA

Search for other papers by Stacey A. Fedewa in
Google Scholar
PubMed Close
,
Ahmedin Jemal Surveillance and Health Services Research, American Cancer Society, Atlanta, Ga., USA

Search for other papers by Ahmedin Jemal in
Google Scholar
PubMed Close
, and
Amy Y. Chen Department of Otolaryngology, Emory University School of Medicine, Atlanta, Ga., USA

Search for other papers by Amy Y. Chen in
Google Scholar
PubMed Close

Food and Drug Administration (FDA) approved the use of several multikinase inhibitors (MKIs) based on recent clinical trials showing their ability to limit disease progression [ 6 , 7 , 8 , 9 , 10 , 11 ]. It is not known, however, whether the

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000449379
Volume/Issue:
Volume 5: Issue 4
Free access
Daniela Dias Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Daniela Dias in
Google Scholar
PubMed Close
,
Inês Damásio Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Inês Damásio in
Google Scholar
PubMed Close
,
Pedro Marques Endocrinology Department, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte (CHULN), Lisbon, Portugal

Search for other papers by Pedro Marques in
Google Scholar
PubMed Close
,
Helder Simões Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Helder Simões in
Google Scholar
PubMed Close
,
Ricardo Rodrigues Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Ricardo Rodrigues in
Google Scholar
PubMed Close
,
Branca Maria Cavaco Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

Search for other papers by Branca Maria Cavaco in
Google Scholar
PubMed Close
, and
Valeriano Leite Endocrinology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Unidade de Investigação em Patobiologia Molecular (UIPM), Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal
Nova Medical School: Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisbon, Portugal

Search for other papers by Valeriano Leite in
Google Scholar
PubMed Close

progress in the treatment of advanced thyroid carcinomas has occurred in the past years with the development of multikinase inhibitors (MKIs) ( 1 , 2 , 3 ). The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved the

Article Type:
Case Report
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-22-0227
Volume/Issue:
Volume 12: Issue 3
Open access
Laura Fugazzola Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Laura Fugazzola in
Google Scholar
PubMed Close
,
Rossella Elisei Unit of Endocrinology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Search for other papers by Rossella Elisei in
Google Scholar
PubMed Close
,
Dagmar Fuhrer Department of Endocrinology, Diabetes and Metabolism, Endocrine Tumour Center at West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Duisburg, Germany

Search for other papers by Dagmar Fuhrer in
Google Scholar
PubMed Close
,
Barbara Jarzab Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Gliwice, Poland

Search for other papers by Barbara Jarzab in
Google Scholar
PubMed Close
,
Sophie Leboulleux Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and Université Paris Saclay, Villejuif, France

Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed Close
,
Kate Newbold Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom

Search for other papers by Kate Newbold in
Google Scholar
PubMed Close
, and
Jan Smit Division of Endocrinology, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

Search for other papers by Jan Smit in
Google Scholar
PubMed Close

years, many new drugs have been investigated for the treatment of progressive RAI-R TC. Currently, 2 multikinase inhibitors (MKI) have been approved for treatment by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), e

Article Type:
Review Article
DOI:
https://doi.org/10.1159/000502229
Volume/Issue:
Volume 8: Issue 5
Free access
Elisa Minaldi Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Elisa Minaldi in
Google Scholar
PubMed Close
,
Virginia Cappagli Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Virginia Cappagli in
Google Scholar
PubMed Close
,
Loredana Lorusso Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Loredana Lorusso in
Google Scholar
PubMed Close
,
Laura Valerio Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Laura Valerio in
Google Scholar
PubMed Close
,
Carlotta Giani Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Carlotta Giani in
Google Scholar
PubMed Close
,
Matilde Viglione Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Matilde Viglione in
Google Scholar
PubMed Close
,
Laura Agate Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Laura Agate in
Google Scholar
PubMed Close
,
Eleonora Molinaro Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Eleonora Molinaro in
Google Scholar
PubMed Close
,
Antonio Matrone Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Antonio Matrone in
Google Scholar
PubMed Close
, and
Rossella Elisei Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Via Paradisa, Pisa, Italy

Search for other papers by Rossella Elisei in
Google Scholar
PubMed Close

Introduction Thanks to the results of DECISION and SELECT trials, sorafenib and lenvatinib are the only MKIs approved by both the U.S. Food and Drug Administration (FDA) and the European Medical Agency (EMA) for the first-line treatment of

Article Type:
Research Article
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-24-0009
Volume/Issue:
Volume 13: Issue 4
Open access
Tim Brandenburg Department of Endocrinology, Diabetes and Metabolism, Endocrine Tumour Center at West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

Search for other papers by Tim Brandenburg in
Google Scholar
PubMed Close
,
Philipp Muchalla Department of Endocrinology, Diabetes and Metabolism, Endocrine Tumour Center at West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

Search for other papers by Philipp Muchalla in
Google Scholar
PubMed Close
,
Sarah Theurer Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
University Duisburg-Essen, Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

Search for other papers by Sarah Theurer in
Google Scholar
PubMed Close
,
Kurt Werner Schmid Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
University Duisburg-Essen, Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

Search for other papers by Kurt Werner Schmid in
Google Scholar
PubMed Close
, and
Dagmar Führer Department of Endocrinology, Diabetes and Metabolism, Endocrine Tumour Center at West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Endocrine Tumour Center at West German Cancer Center, Member of ENDO-ERN and EURACAN, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

Search for other papers by Dagmar Führer in
Google Scholar
PubMed Close

PAX8 staining showed a nuclear expression pattern. Scale bar, 100 µm. Fig. 3. Representative neck CT scans showing response of the PSCC of the thyroid to combined MKI treatment (baseline, a ) at 3 ( b ) and 6 ( c ) months and regrowth

Article Type:
Case Report
DOI:
https://doi.org/10.1159/000518055
Volume/Issue:
Volume 10: Issue 6
Free access
Carla Colombo Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Carla Colombo in
Google Scholar
PubMed Close
,
Daniele Ceruti Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Daniele Ceruti in
Google Scholar
PubMed Close
,
Simone De Leo Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy

Search for other papers by Simone De Leo in
Google Scholar
PubMed Close
,
Grzegorz Bilo Department of Cardiology, San Luca Hospital, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

Search for other papers by Grzegorz Bilo in
Google Scholar
PubMed Close
,
Matteo Trevisan Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Matteo Trevisan in
Google Scholar
PubMed Close
,
Noemi Giancola Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Noemi Giancola in
Google Scholar
PubMed Close
,
Claudia Moneta Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Claudia Moneta in
Google Scholar
PubMed Close
,
Gianfranco Parati Department of Cardiology, San Luca Hospital, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

Search for other papers by Gianfranco Parati in
Google Scholar
PubMed Close
,
Luca Persani Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Luca Persani in
Google Scholar
PubMed Close
, and
Laura Fugazzola Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Laura Fugazzola in
Google Scholar
PubMed Close

Introduction Multikinase inhibitors (MKIs) with strong anti-angiogenetic action are frequently used for the treatment of advanced radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) or medullary thyroid cancers (MTCs) ( 1 , 2

Article Type:
Research Article
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-23-0047
Volume/Issue:
Volume 12: Issue 4
Open access
Grace Segall Eli Lilly and Company, Indianapolis, IN, USA

Search for other papers by Grace Segall in
Google Scholar
PubMed Close
,
Ravinder Singh Eli Lilly and Company, Indianapolis, IN, USA

Search for other papers by Ravinder Singh in
Google Scholar
PubMed Close
,
Min-Hua Jen Eli Lilly and Company, Indianapolis, IN, USA

Search for other papers by Min-Hua Jen in
Google Scholar
PubMed Close
,
Isaac Sanderson Adelphi Real World, Bollington, UK

Search for other papers by Isaac Sanderson in
Google Scholar
PubMed Close
,
Alex Rider Adelphi Real World, Bollington, UK

Search for other papers by Alex Rider in
Google Scholar
PubMed Close
,
Katie Lewis Adelphi Real World, Bollington, UK

Search for other papers by Katie Lewis in
Google Scholar
PubMed Close
, and
Urpo Kiiskinen Eli Lilly and Company, Indianapolis, IN, USA

Search for other papers by Urpo Kiiskinen in
Google Scholar
PubMed Close

MTC for whom treatment with systemic therapy is planned ( 12 ). Systemic therapies in advanced or metastatic MTC (aMTC) include multikinase inhibitors (MKIs) and selective RET inhibitors ( 12 , 13 ). ESMO treatment guidelines from April 2022

Article Type:
Research Article
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-23-0172
Volume/Issue:
Volume 13: Issue 1
Open access
Carla Gambale Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Carla Gambale in
Google Scholar
PubMed Close
,
Alessandro Prete Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Alessandro Prete in
Google Scholar
PubMed Close
,
Chiara Romei Department of Diagnostic Imaging, Unit of Radiology, Pisa University Hospital, Pisa, Italy

Search for other papers by Chiara Romei in
Google Scholar
PubMed Close
,
Alessandro Celi Department of Surgery, Medicine, Molecular Biology and Critical Care, Respiratory Pathophysiology Unit, Pisa University Hospital, Pisa, Italy

Search for other papers by Alessandro Celi in
Google Scholar
PubMed Close
,
Rossella Elisei Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Rossella Elisei in
Google Scholar
PubMed Close
, and
Antonio Matrone Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Antonio Matrone in
Google Scholar
PubMed Close

advanced/metastatic ( 1 ). According to European Medicines Agency (EMA) indications, two multikinase inhibitors (MKIs) (i.e. vandetanib and cabozantinib) and one highly selective RET inhibitor (i.e. selpercatinib) have been approved for the treatment of

Article Type:
Case Report
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-24-0189
Volume/Issue:
Volume 13: Issue 5
Open access